ProMIS Neurosciences Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Neil K. Warma

Amministratore delegato

US$40.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	3.5yrs
Durata media del Consiglio di amministrazione	6.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Neil K. Warma (61 yo)

less than a year

Mandato

US$40,000

Compensazione

Mr. Neil K. Warma, MBA, serves as Chief Executive Officer and President of ProMIS Neurosciences, Inc. from August 1, 2024 and has been its Director since December 30, 2023 and was its Interim Chief Executi...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Eugene Williams	Co-Founder & Chairman	9.4yrs	US$275.00k	0.79% $ 164.6k
Neil K. Warma	CEO, President & Director	less than a year	US$40.00k	Nessun dato
Neil Cashman	Co-Founder	20.5yrs	US$378.82k	0.57% $ 118.3k
Gavin Malenfant	Chief Operating Officer	3.1yrs	US$435.90k	0.013% $ 2.7k
Daniel Geffken	Chief Financial Officer	7.7yrs	US$142.40k	0.029% $ 6.0k
Johanne Kaplan	Chief Development Officer	8.3yrs	US$525.57k	0.024% $ 5.0k
David Wishart	Chief Physics Officer	3.5yrs	Nessun dato	Nessun dato
Dennis Chen	Head of Manufacturing & Senior Consultant	no data	Nessun dato	Nessun dato
Larry Altstiel	Chief Medical Officer	2.6yrs	Nessun dato	Nessun dato

3.5yrs

Durata media

65yo

Età media

Gestione esperta: Il team dirigenziale di PMN è considerato esperto (durata media dell'incarico 3.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Eugene Williams	Co-Founder & Chairman	9.4yrs	US$275.00k	0.79% $ 164.6k
Neil K. Warma	CEO, President & Director	3.5yrs	US$40.00k	Nessun dato
Neil Cashman	Co-Founder	17.8yrs	US$378.82k	0.57% $ 118.3k
William Wyman	Independent Director	10.7yrs	US$40.00k	0.31% $ 64.8k
William Mobley	Member of Scientific Advisory Board	7.4yrs	Nessun dato	Nessun dato
Patrick Kirwin	Independent Director	9.4yrs	US$40.00k	0.49% $ 102.0k
Joshua Mandel-Brehm	Independent Director	3.2yrs	US$40.00k	0% $ 0
Sharon Cohen	Member of Scientific Advisory Board	6.7yrs	Nessun dato	Nessun dato
Andre Strydom	Member of Scientific Advisory Board	5.3yrs	Nessun dato	Nessun dato
Michelle Hastings	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Madge Shafmaster	Lead Independent Director	3.2yrs	US$40.00k	1.04% $ 214.5k
Carsten Korth	Member of Scientific Advisory Board	2.8yrs	Nessun dato	Nessun dato

6.7yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PMN sono considerati esperti (durata media dell'incarico 6.7 anni).

ProMIS Neurosciences Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media